Posts Tagged ‘biotech’
Partner Gregory Sichenzia Writes “Jumpstarting the IPO Market: Economic Factors to Watch in 2016” for Huffington Post
April 5, 2016 – Partner Greg Sichenzia wrote an article for Huffington Post Business titled “Jumpstarting the IPO Market: Economic Factors to Watch in 2016.” The article discusses recent macro and micro economic trends that may spark an uptick in IPO activity. These include an increase in public filings since January, greater stability in the…
Read MorePartner Gregory Sichenzia Quoted on Biotech IPOs
February 22, 2016 – Partner Greg Sichenzia was quoted in a Law360 article titled “More Biotech IPOs Likely To Rely On Insiders Amid Slump.” The article discussed that more biotech companies are relying on support from inside investors to close deals due to weaker demand in the broader market. Greg noted that insider participation can…
Read MorePartner Gregory Sichenzia Quoted on the Impact of Market Volatility on Biotech Issuers
January 19, 2016 – Partner Greg Sichenzia, whose clients include Swedish and Israeli biotech companies, was quoted in a Law360 article titled “Market Volatility Cools Attys’ Hopes For ‘JPMorgan Bounce’.” not assigned biotech | law360 | srff
Read More
